Truist Financial Maintains Progyny(PGNY.US) With Buy Rating
Leerink Partners Downgrades Progyny(PGNY.US) to Hold Rating, Cuts Target Price to $25
A Quick Look at Today's Ratings for Progyny(PGNY.US), With a Forecast Between $24 to $31
Progyny: Growth Potential Acknowledged Amid Execution Concerns – Hold Rating Maintained
Progyny (PGNY) Gets a Buy From Barclays
Progyny's Growth Trajectory and Market Differentiation Affirm Buy Rating
Progyny Analyst Ratings
Progyny Price Target Cut to $31.00/Share From $36.00 by JMP Securities
Truist Financial Reaffirms Their Buy Rating on Progyny (PGNY)
Progyny Hold Rating: Adjusted Price Target and Concerns Over Uncertain Growth Trajectory
Progyny Analyst Ratings
Leerink Partners Downgrades Progyny to Market Perform, Lowers Price Target to $25
Barclays Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $30
JMP Securities Maintains Progyny(PGNY.US) With Buy Rating, Cuts Target Price to $31
Progyny's Resilience and Growth Prospects Affirmed With Buy Rating Despite Near-Term Challenges
Barclays Maintains Progyny(PGNY.US) With Buy Rating, Maintains Target Price $30
Barclays Keeps Their Buy Rating on Progyny (PGNY)
Progyny Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Progyny (PGNY) and Nanosonics Limited (OtherNNCSF)
Analysts Are Bullish on Top Healthcare Stocks: Progyny (PGNY), Regeneron (REGN)
No Data